A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity

被引:128
作者
Li, AP [1 ]
机构
[1] Phase 1 Mol Technol Inc, Santa Fe, NM 87505 USA
关键词
idiosyncratic hepatotoxicity; multiple determinant hypothesis; idiosyncratic drug toxicity; reactive metabolites; drug-drug interaction; drug metabolisms; toxicogenomics;
D O I
10.1016/S0009-2797(02)00051-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Idiosyncratic drug toxicity is generally believed to be a phenomenon that cannot be readily evaluated experimentally. Reasons for this difficulty include the following: 1. It is a rare event (< 1/5000) and therefore impossible to be studied in clinical trials; 2. It is a human-specific event not detectable in experimental animals. To aid the understanding of idiosyncratic toxicity and to develop an experimental strategy for this phenomenon, a hypothesis is proposed, The hypothesis states that the low frequency of idiosyncratic drug toxicity is due to the requirements for the occurrence of multiple critical and discrete events, with the probability for the occurrence of idiosyncratic drug toxicity as a product of the probabilities of each event. The key determinants of these critical events are proposed to be: 1. Chemical properties: 2. exposure: 3. environmental factors: and 4. genetic factors. Based on this hypothesis. idiosyncratic drug toxicity can be evaluated experimentally via studying these key determinants. The chemical properties critical to idiosyncratic drug toxicity are identified via a review of the common properties of drugs that cause idiosyncratic liver toxicity. These properties include: 1. Formation of reactive metabolites. 2. Metabolism by P450 isoforms. 3. Preponderance of P450 inducers, and 4. Occurrence of clinically significant pharmacokinetic interactions with co-administered drugs. Based on this review, it is proposed that these common properties may be useful experimental endpoints for the prediction and therefore avoidance of the selection of drug candidates with idiosyncratic drug toxicity for further development. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:7 / 23
页数:17
相关论文
共 132 条
[71]   Cyclosporine and nonsteroidal antiinflammatory drugs: Exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis [J].
Kovarik, JM ;
Mueller, EA ;
Gerbeau, C ;
Tarral, A ;
Francheteau, P ;
Guerret, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (04) :336-343
[72]   HEPATIC TOXICITY ASSOCIATED WITH 2'-3'DIDEOXYINOSINE IN CHILDREN WITH AIDS [J].
LACAILLE, F ;
ORTIGAO, MB ;
DEBRE, M ;
ROUZIOUX, C ;
BROUSSE, N ;
BLANCHE, S .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 1995, 20 (03) :287-290
[73]  
LACROIX C, 1990, ARZNEIMITTELFORSCH, V40-1, P76
[74]   CROSS HEPATOTOXICITY BETWEEN TRICYCLIC ANTIDEPRESSANTS [J].
LARREY, D ;
RUEFF, B ;
PESSAYRE, D ;
DANAN, G ;
ALGARD, M ;
GENEVE, J ;
BENHAMOU, JP .
GUT, 1986, 27 (06) :726-727
[75]   GENETICALLY-DETERMINED OXIDATION POLYMORPHISM AND DRUG HEPATOTOXICITY - STUDY OF 51 PATIENTS [J].
LARREY, D ;
TINEL, M ;
AMOUYAL, G ;
FRENEAUX, E ;
BERSON, A ;
FOUINFORTUNET, H ;
BABANY, G ;
LETTERON, P ;
IGLICKI, F ;
SLAMA, JL ;
HABERSETZER, F ;
PESSAYRE, D ;
BENHAMOU, JP .
JOURNAL OF HEPATOLOGY, 1989, 8 (02) :158-164
[76]   Genetic predisposition to drug-induced hepatotoxicity [J].
Larrey, D ;
Pageaux, GP .
JOURNAL OF HEPATOLOGY, 1997, 26 :12-21
[77]   SPECIFICITY OF IN-VITRO COVALENT BINDING OF TIENILIC ACID METABOLITES TO HUMAN LIVER-MICROSOMES IN RELATIONSHIP TO THE TYPE OF HEPATOTOXICITY - COMPARISON WITH 2 DIRECTLY HEPATOTOXIC DRUGS [J].
LECOEUR, S ;
BONIERBALE, E ;
CHALLINE, D ;
GAUTIER, JC ;
VALADON, P ;
DANSETTE, PM ;
CATINOT, R ;
BALLET, F ;
MANSUY, D ;
BEAUNE, PH .
CHEMICAL RESEARCH IN TOXICOLOGY, 1994, 7 (03) :434-442
[78]  
Lederman JC, 2001, AM J GASTROENTEROL, V96, P3474
[79]   Role of CYP2D6 in the N-hydroxylation of procainamide [J].
Lessard, E ;
Fortin, A ;
Belanger, PM ;
Beaune, P ;
Hamelin, BA ;
Turgeon, J .
PHARMACOGENETICS, 1997, 7 (05) :381-390
[80]   Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin [J].
Li, AP ;
JurimaRomet, M .
CELL BIOLOGY AND TOXICOLOGY, 1997, 13 (4-5) :365-374